| Literature DB >> 32397270 |
Oleksandr Kolyvushko1, Juliane Latzke1, Ismail Dahmani2, Nikolaus Osterrieder1, Salvatore Chiantia2, Walid Azab1.
Abstract
Exposure of phosphatidylserine (PS) in the outer leaflet of the plasma membrane is induced by infection with several members of the Alphaherpesvirinae subfamily. There is evidence that PS is used by the equine herpesvirus type 1 (EHV-1) during entry, but the exact role of PS and other phospholipids in the entry process remains unknown. Here, we investigated the interaction of differently charged phospholipids with virus particles and determined their influence on infection. Our data show that liposomes containing negatively charged PS or positively charged DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium) inhibited EHV-1 infection, while neutral phosphatidylcholine (PC) had no effect. Inhibition of infection with PS was transient, decreased with time, and was dose dependent. Our findings indicate that both cationic and anionic phospholipids can interact with the virus and reduce infectivity, while, presumably, acting through different mechanisms. Charged phospholipids were found to have antiviral effects and may be used to inhibit EHV-1 infection.Entities:
Keywords: EHV-1; alphaherpesvirus; inhibition; pathogen host interaction; phosphatidylserine
Year: 2020 PMID: 32397270 PMCID: PMC7281745 DOI: 10.3390/pathogens9050359
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Phospholipids inhibit equid herpesvirus type 1 (EHV-1) infection. (A) Effects of lipid concentration on EHV-1 infection. Equine dermal (ED) cells were treated with 200 μM or 300 μM of small unilamellar vesicles (SUVs) (phosphatidylserine (PS); N-[1-(2,3-Dioleoyloxy) propyl]-N,N,N-trimethylammonium (DOTAP):phosphatidylcholine (PC) 1:1; or PC SUVs) for 3 h and infected with EHV-1 at an MOI of 0.1. GFP expression at 24 h post infection was measured by FACS. (B) ED cells were treated with 300 μM of PS SUVs for different times (0; Premix Virus-Liposomes, 1, 2, or 3 h) and then infected with EHV-1 at MOI of 0.1. GFP expression at 24 h post infection was measured by FACS. Control: cells infected with viruses without previous treatment with lipids. 3H Transient: SUVs were removed by washing the cells three times with PBS before infection. (C) Cell viability assay, cells were treated with SUVs composed of PS, DOTAP:PC (1:1), or PC lipids for 24 h. Mock-treated cells and cells treated with H2O2 (30%) were used as the 100% and 0% viability controls, respectively. No significant differences between treatment groups and mock control were found. p < 0.05, Kolmogorov–Smirnov normality test followed by one-way ANOVA with Dunnett’s multiple comparison test. Asterisks indicate a significant difference of lipid-treated to the control non-treated cells.
Figure 2Virus interaction with phospholipids. (A) EHV-1-RFP (MOI = 5) was mixed with fluorescently labeled large unilamellar vesicles (LUVs) of PS, PC or DOTAP:PC (1:1). The mixture was applied to ED cells that were incubated for 1 h on ice. Green: pseudocolored fluorescently labeled LUVs; Red: RFP-labeled viruses; Blue: DAPI stained nucleus. Merge panels: dotted lines represent the boundaries of cells. Scale bar = 10 μm. (B) Binding of EHV-1-RFP to giant unilamellar vesicles (GUVs). Pictures of GUVs made of PS:PC (1:1), DOTAP:PC (1:1), and PC with bound RFP-labeled virus. Scale bars indicate 10 µm. (C) Quantification of the average signal in 15–21 GUVs from two independent experiments for each lipid compositions: PC, PC:PS (1:1), or DOTAP:PC (1:1). **** p < 0.0001 (one-way ANOVA with Dunnett’s test was used to correct for multiple comparisons). (D) Surface plasmon resonance (SPR) analysis of EHV-1 interactions with model membrane composed of neutral, cationic, or anionic phospholipids. Representative sensorgrams after curve alignment show the virus association to the immobilized lipid monolayer composed of DOTAP 100 mol%, PC 100 mol%, or PS 100 mol%. RU: corrected SPR response unit.